Educating Groups Influencing Generic Drug Use

项目摘要 自2000年以来，美国的处方药支出增长了114%。一种方法来对抗不断上升的处方 药品费用是鼓励使用仿制药。考虑到美国的医疗保险和医疗补助计划， 通过扩大非专利药的使用，估计今后十年可节省890亿美元。虽然成本- 仿制药的节省是明确的，仿制药市场渗透率因药物类别而异，由处方者， 和地理位置。有证据表明，仿制药的使用在很大程度上受到某些关键群体的影响。 对仿制药的行为和看法。虽然被认为是有影响力的， 影响是异质的，取决于对非专利药的经验和看法等因素。 因此，针对可能限制仿制药使用的所有类型障碍的有效教育工作是一个关键 需要的拟议研究的目的是了解关键群体的作用及其影响的程度。 对非专利药物使用的影响，以便提供额外和有效的教育宣传， 信息需求。为此，我们将使用混合方法来解决三个研究目标：1） 研究影响美国仿制药使用的关键群体，并确定其性质和程度 影响; 2）确定关键群体对仿制药的信息需求， 这些关键群体目前和希望通过何种方式获得与保健有关的教育材料;以及3） 开发、测试和修订教育材料，以满足关键群体对通用 毒品六个先验定义的关键组包括患者/护理人员、处方医生、药剂师、保险公司、 处方管理人员、州卫生政策制定者和制药商。康贝特人将以 使用系统性回顾结合创新性分析， 多个公开可用的数据集。定性的关键线人访谈将开发信息的概况 对仿制药的总体需求和对具有独特性质的特定药物组的需求。发育 小组讨论会将结合对主要信息提供者的访谈和调查，编制和完善教育材料。的 这项研究的预期成果是提供信息、战略和教育材料， 克服在美国使用仿制药的障碍

Project Abstract Spending on prescription drugs in the U.S. has risen 114% since 2000. One way to combat rising prescription drug costs is to encourage use of generic drugs. Just considering U.S. Medicare and Medicaid programs, an estimated $89 billion could be saved over the next decade through expanded generic drug use. While the cost- savings of generics is clear, generic drug market penetration varies across classes of drugs, by prescribers, and by geographic location. Evidence shows that generic drug use is largely impacted by certain key groups' behaviors and perceptions towards generic drugs. While believed to be influential, the extent of each groups influence is heterogeneous and dependent on factors such as experiences and perceptions with generic drugs. Thus, effective educational efforts to target all types of barriers that may limit generic drug use are a critical need. The purpose of the proposed research is to understand roles of key groups and the extent of their influence on generic drug use in order to provide additional and effective educational outreach to meet their informational needs. To this end, we will use a mixed-methods approach to address three study aims: 1) to study the key groups influencing generic drug use in the U.S. and to determine the nature and extent of their influence; 2) to determine the key groups' informational needs regarding generic drugs and establish the current and desired means by which these key groups receive healthcare-related educational material; and 3) to develop, test, and revise educational materials to address key groups' informational needs regarding generic drugs. The six a priori defined key groups include patients/caregivers, prescribers, pharmacists, insurance formulary managers, state health policy makers, and pharmaceutical manufacturers. We will determine the nature and extent of each groups influence using systematic review combined with innovative analyses of multiple publicly available datasets. Qualitative key informant interviews will develop profiles of informational needs for generic drugs overall and for specific drug groups that have unique properties. Developmental panels combined with key informant interviews and surveys will develop and refine educational materials. The expected outcomes of this study are provision of information, strategies, and educational materials to overcome barriers to generic drug use in the U.S.